Ph 2 Study of IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Conditions:   Melanoma Stage III;   Melanoma Stage IV;   Inoperable Disease Interventions:   Drug: Interleukin-2;   Drug: Ipilimumab;   Drug: Nivolumab Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Clinigen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials